Salix Pharmaceuticals, Ltd.
  • Россия
  • Украина

Salix Pharmaceuticals, Ltd.

Contact Details

8510 Colonnade Center Dr, Raleigh, North Carolina, USA 27615-3050
(919) 862-1000
8510 Colonnade Center Dr, Raleigh, North Carolina, USA 27615-3050

General Information

Salix Pharmaceuticals, Ltd. is a large-sized organization in the pharmaceutical preparation companies industry located in Raleigh, NC. It opened its doors in 2015 and now has an estimated $123.8 million in yearly revenue and 887 employees.

Contact Information

Phone(919) 862-1000
Fax(919) 862-1095
Website 1
Thomson Reuters PermID4295900388


Drug NameCondition
METOZOLV ODTHyperacidity, GERD, and ulcers
RELISTORConstipation and bowel cleansers
XIFAXAN 550mgHepatic encephalopathy


NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO and President$6,600,959201311.2%
CFO and Divisional Executive VP$2,039,99320139.9%
Divisional Executive VP and Other Executive Officer$1,968,771201310.9%
Divisional Executive VP$1,802,05420139.0%
Chairman of the Board$431,0002003-24.7%
Divisional Former Vice President and Former Chief Medical Officer$402,19220069.3%
Chief Medical Officer and Divisional Vice President$246,1402003-8.0%
CEO, President and Director
Other Corporate Officer

Corporate Data


  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Drugs Acting On The Gastrointestinal Or Genitourinary System

Company Size

Sales Volume$13.5 million


Ticker SymbolSLXP
ExchangeNASDAQ Global Select Market
Year Founded2015


52-Week Range91.47 - 172.75
Average Volume (1M)6,544,812
Forward P/E153.55x
Trailing P/E140.44x
Market Cap.$11,098.4 Million
Last Dividend Amount0
1y Target Price Est.153.7


Summary of Form-D Filings

    Filing History

  • Salix Pharmaceuticals Ltd has filed 1 Form Ds since 2008. Of these filings, 1 has been for a unique offering.
  • Through these filings, they have raised $750,000,000.
  • They have not paid finder`s fees or sales commissions in connection with these offerings.
  • They have not used any of the proceeds from its offerings to pay officers or directors.
  • The types of securities they have issued are Debt.
  • They have relied on the following exemptions in past filings Rule 506(b).

    Analysis of Past Filings

  • Salix Pharmaceuticals Ltd has filed about as many filings as an average company in the Pharmaceuticals category.
  • They have had about as many unique offerings as an average company in the Pharmaceuticals category.
  • The total amount raised they have raised is 25,098% higher than the average for a company in the Pharmaceuticals category.


Period EndingDec. 31, 2014Sep. 30, 2014Jun. 30, 2014Mar. 31, 2014
Total Revenue13,476341,547375,540402,979
Cost of Revenue30,21886,111104,567116,940
Gross Profit(16,742)255,436270,973286,039
Research Development66,81336,67825,57641,222
Selling General and Administrative137,072177,582138,362207,098
Depreciation and Amortization216,60054,04253,91053,897
Other Operating Expenses(13,786)76,54910,1494,039
Total Operating Expenses436,917430,962332,564423,196
Other Income/Expenses Net----
Earnings Before Interest and Taxes(423,441)(89,415)42,976(20,217)
Interest Expense42,63242,99842,44242,710
Income Before Tax(467,326.9)(134,150)511(62,618)
Income Tax Expense(179,683)(41,042)93(28,041)
Minority Interest----
Net Income from Continuing Ops(287,644)(93,108)418(34,577)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income(287,644)(93,108)418(34,577)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares(287,644)(93,108)418(34,577)